Change - Announcement of Appointment::APPOINTMENT OF NON-INDEPENDENT NON-EXECUTIVE DIRECTOR

Issuer & Securities

Issuer/ Manager
ASIAMEDIC LIMITED
Securities
ASIAMEDIC LIMITED - SG0505000059 - 505
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
11-Feb-2022 18:40:21
Status
New
Announcement Sub Title
APPOINTMENT OF NON-INDEPENDENT NON-EXECUTIVE DIRECTOR
Announcement Reference
SG220211OTHRBPSB
Submitted By (Co./ Ind. Name)
Stanley Woo
Designation
Group Financial Controller
Description (Please provide a detailed description of the event in the box below)
Sponsor statement:
This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd, in compliance with Rule 226 of the Catalist Rules. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 63194954.

Additional Details

Date Of Appointment
11/02/2022
Name Of Person
Aona Liu
Age
29
Country Of Principal Residence
China
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
Ms Aona Liu, a controlling shareholder of the Company, has the relevant qualification and experience in healthcare. Ms Liu possesses a Master of Science in International Health Management. She has also been involved in the leadership and management roles in Luye Medical Group group of companies since 2017. She has experience in the areas of change management, strategy, fund raising and team development.

The Board of Directors of the Company ("Board"), having considered the recommendation of the Nominating Committee and having reviewed and considered the qualifications, working experience and suitability of Ms Liu, is of the view that she has the requisite experience and capability to be appointed as a Director of the Company. Accordingly, the Board has approved the appointment of Ms Liu as a Director of the Company.
Whether appointment is executive, and if so, the area of responsibility
The appointment is non-executive.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Non-Independent Non-Executive Director

Professional qualifications
Bachelor of Science in Economics (with Honours), The University of Edinburgh
Master of Arts in Economics (with Honours), The University of Edinburgh
Master of Science in International Health Management, Imperial College London

Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Ms Liu is currently the Executive Chairperson & Chairperson of the Board of Luye Medical Group group of companies, Singapore and China. Luye Medical Group Pte. Ltd., the controlling shareholder of the Company, is part of the Luye Medical Group group of companies.

Ms Liu, her father (Mr Liu Dianbo), her mother (Mdm Wang Cuilian) and her sister (Ms Alina W Liu) are beneficiaries of The Asoka Trust. The Asoka Trust and its beneficiaries are deemed to have an interest in the ordinary shares of the Company held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the Securities and Futures Act 2001.
Conflict of interests (including any competing business)
As the Executive Chairperson and Chairperson of the Board of Luye Medical Group group of companies, Ms Liu would be overseeing all their businesses and operations. In 2017, the Company adopted a shareholders' general mandate, which has been renewed on an annual basis, for recurrent interested person transactions with two interested persons including OncoCare Medical Pte. Ltd. (formerly known as Brookline Medical Pte. Ltd.) which is part of Luye Medical Group group of companies. To allay any concerns on future potential conflict of interests which may arise between (a) the Company and its subsidiaries; and (b) Luye Medical Group group of companies, Ms Liu will disclose any potential conflict of interests to the Board of the Company and abstain from participating in its deliberations of such matters.

Working experience and occupation(s) during the past 10 years
2020-Current
Executive Chairperson & Chairperson of the Board
Luye Medical Group group of companies, Singapore & China

2018- Current
Founder CEO
Philosojoy Pte. Ltd., Singapore

2017-2018
Executive Director
Luye Medical Innovation Centre
Luye Medical Group group of companies, Singapore & China

2016-2017
Global Strategy Planning & Business Development Manager
Luye Medical Group group of companies, Singapore & China
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Please refer to Form 1.
Deemed interest of 512,098,062 ordinary shares (45.74% of issued share capital) in the Company.
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Please refer to the attachment.

Present
Please refer to the attachment.


(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
The Director will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange.

Attachments

Directorships.pdf
Total size =173K